Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...
Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results